Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 7/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28976697 | 0.94 | SCN10A (0.37) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL28976525 | 0.82 | SCN10A (0.35) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL28976575 | 0.75 | SCN10A (0.37) | FFAR2SCN10APARP1PARP2 | |
| SCHEMBL28976927 | 0.75 | PARP1 (0.33) | DGAT1SOAT1FFAR2SCN10APARP1 | |
| SCHEMBL28976577 | 0.75 | SCN10A (0.33) | FFAR2SCN10A | |
| SCHEMBL29252887 | 0.73 | KDM1A (0.34) | PARP1PARP2 | |
| SCHEMBL28976931 | 0.73 | SCN10A (0.40) | FFAR2SCN10APARP1PARP2 | |
| SCHEMBL28976382 | 0.72 | SCN10A (0.39) | FFAR2SCN10APARP1PARP2 | |
| SCHEMBL28976476 | 0.71 | SCN10A (0.41) | DGAT1SCN10APARP1PARP2 | |
| SCHEMBL28976948 | 0.70 | MAP3K14 (0.35) | SCN10APARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115884810-A | Imidazopyridazines as IL-17 modulators | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |